JP 5161718
Patent Title:
"Hepatopathy model animal and method for screening drug or food material to ameliorate or prevent hepatopathy by using the animal"
PROBLEM TO BE SOLVED: To provide a new hepatopathy model animal constructing a simple, accurate and useful in vivo evaluation system, available at a remarkably reduced cost and causing little ethical problems compared with conventional techniques, a method for preparing the animal, and a method for exhaustively/screeningly searching a hepatopathy treating agent and a food material having hepatic function improving or hepatopathy preventing function for mammals such as human, in contrast with conventional model animals practically unable to perform such searching, even by using the in vivo evaluation system to use the hepatopathy model animal.
SOLUTION: The hepatopathy model animal is a larva of a holometabolous insect having treatable damage on its fat body and/or intestinal canal by administration of a compound. There is further provided a screening method for the drug or food material effective for ameliorating or preventing hepatopathy of mammals by using the hepatopathy model animal.
Issued - Dec 21, 2012
Genome Pharmaceuticals Institute Co., Ltd. and The University of Tokyo
Patent Application Number:
JP 2008-063817
Patent Title:
"Method for evaluating degree of contamination caused by pathogenic microorganism of test specimen"
PROBLEM TO BE SOLVED: To provide a method capable of comprehensively evaluating the condition of contamination caused by a pathogenic microorganism of a test specimen without using a test animal such as a mouse and without carrying out a complex process.
SOLUTION: The method for evaluating the degree of the contamination caused by the pathogenic microorganism of the test specimen includes evaluating whether toxicity is exhibited in a larva or not when a sample containing the microorganism separated from the test specimen and/or a product produced by the microorganism is administered to the larva of a holometaboly-type insect. Especially, the test specimen is preferably an environmental sample in the method. More preferably, the environmental sample is soil, underground water, river water, lake water, seawater or air-borne fungi in the method.
Filed - Filed Mar 13, 2008
Genome Pharmaceuticals Institute Co., Ltd.,
Patent Number:
JP 5260915
Patent Title:
"Toxicity testing method"
PROBLEM TO BE SOLVED: To provide a toxicity testing method which enables the replacement of an acute toxicity test with respect to various drugs or food materials of a mammal having not only a problem of economical efficiency or labor but also a moral problem without bringing about a problem from an aspect of cost and morals and reducing the meaning of the test.
SOLUTION: The toxicity testing method is a method for evaluating the acute toxicity of the mammal by an examination target showing cytotoxicity with respect to the mammal and performed by administering the examination target to the larva of a holometabolous insect to calculate the LD 50 value of the larva. Further, this toxicity testing method is performed by measuring the metabolic state of the examination target in the larva of the holometabolous insect to which the examination target is administered.
Issued - May 2, 2013
Genome Pharmaceuticals Institute Co., Ltd.,
Patent Number:
JP 5303209
Patent Title:
"Evaluating method, screening method, and manufacturing method of matter for lowering blood sugar level"
PROBLEM TO BE SOLVED: To provide cost-effective methods for accurately and excellently screening, evaluating and manufacturing diabetic curative drugs in which few ethical problems exist, additionally also cost-effective laboratory animals under specific condition to preferably be used in the above methods with few ethical problems.
SOLUTION: This is the method for evaluating as to whether a test substance is the matter which lowers human blood sugar level or not, characterized by comprising a process (a) to raise glucose (B) concentration in fat body or blood of a target invertebrate animal by allowing this invertebrate animal to ingest glucose (A), a process (b) to administer the above test substance to the target invertebrate animal with its glucose (B) concentration in fat body or blood increased which is obtained from the above process (a), and a process (c) to measure the glucose (B) concentration in fat body or blood of the invertebrate animal injected with the above test substance.
Issued - Jun 28, 2013
Genome Pharmaceuticals Institute Co., Ltd.,
Patent Number:
US 8313779, JP 5394233, EU 2133693
Patent Title:
"Evaluation method and screening method for substance having action of activating/suppressing innate immunity, agent and food product for activating/suppressing innate immune mechanism and method for producing the same"
To provide an evaluation method and a screening method capable of eliminating a substance that disturbs in vivo kinetics in an individual and capable of simply and easily searching a substance having an action of activating/suppressing an innate immune mechanism without being affected by LPS derived from bacteria, which can be contaminated during the search, as well as a drug and a food for activating/suppressing the innate immune mechanism, and methods of producing the same. The present invention provides a method of evaluating or screening the substance having the action of activating/suppressing the innate immune mechanism using a muscular contraction of an organism having the innate immune mechanism as an indicator, and methods of producing the drug and the food for activating/suppressing the innate immune mechanism. Also, an innate immunity activator and the food having the action of activating the innate immune mechanism containing the substance having the action of contracting the muscle of the organism having the innate immune mechanism, and an innate immunity suppressor and the food having the action of suppressing the innate immunity containing the substance having the action of suppressing the contraction of the muscle of the organism having the innate immune mechanism are provided.
Issued - Nov 20, 2012
Genome Pharmaceuticals Institute Co., Ltd., the University of Tokyo and Imagine Global Care Corporation,
Patent Number:
JP 4668900
Patent Title:
"Method of screening sample having antiviral activity against virus with ability to infect organism exhibiting acquired immune mechanism by use of individual organism, or its cultured cell, exhibiting natural immune mechanism only, and method of estimating the antiviral activity by use of individual organism, or its cultured"
Results have proved that infection deaths by nuclear polyhedrosis viruses of silkworm larvae can be remedied by ganciclovir, foscarnet, vidarabine and ribavirin used as therapeutic drugs for cytomegalus virus infection at human clinic. Findings indicate that the use of individual organism, or its cultured cell, exhibiting natural immune mechanism only, such as silkworm larva, leads to realization of screening of a sample having an antiviral activity against virus with ability to infect an organism exhibiting acquired immune mechanism, such as human, and realization of estimation of the antiviral activity.
Issued - Jan 21, 2011
Genome Pharmaceuticals Institute Co., Ltd.,
Patent Number:
JP 4733080
Patent Title:
"Method for screening compound having antimicrobial activity to pathogenic microbe infecting living thing having acquired immunologic mechanism by utilizing living thing having only natural immunologic mechanism, and method for evaluating antimicrobial activity by utilizing living thing having only natural immunologic mechanism"
PROBLEM TO BE SOLVED: To provide a model useful for developing an antimicrobial agent for a microbial infectious disease in a living thing having an acquired immunologic mechanism, which is a model for microbial infection utilizing a living thing having only a natural immunologic mechanism.
SOLUTION: It is studied whether a silkworm larva having only the natural immunologic mechanism is useful as an antimicrobial agent evaluation system or not. It is found that the silkworm larva dies of infection by injection of Staphylococcus aureus or Pseudomonas aeruginosa into the silkworm larva. Surprisingly, the effect of the antimicrobial agent to the silkworm larva agrees with clinical effectiveness of medicines to a human which is a living thing having the acquired immunologic mechanism.
Issued - Apr 28, 2011
Genome Pharmaceuticals Institute Co., Ltd.,
Patent Number:
JP 5103491
Patent Title:
"Method of screening compound having antimicrobial activity on pathogenic microorganism infecting organism having acquired immune mechanism by using larva of insect having only natural immune mechanism, and method of evaluating antimicrobial activity by using larva of insect having only natural immune mechanism"
PROBLEM TO BE SOLVED: To provide an effective model for developing antimicrobial agent for microbe infection in an organism having acquired immune mechanism, wherein the model of microbe infection using the organism having only natural immune mechanism.
SOLUTION: Whether the larva of a silkworm is useful or not as an antimicrobial agent evaluation system is investigated. It is found out that the larva of the silkworm is died by infection on the injection of Staphylococcus aureus or Pseudomonas aeruginosa to the larva of the silkworm. The effect of the antimicrobial agent for the larva of the silkworm is surprisingly agrees with the clinical efficacy of these agent on human i.e. an organism having acquired immune mechanism.
Issued - Oct 5, 2012
Genome Pharmaceuticals Institute Co., Ltd.,
Patent Number:
JP 4914200
Patent Title:
"Medicine for preventing or treating infectious disease, and method for producing the same and evaluation method and screening method for the same and method for evaluating pathogenesis of pathogenic bacterium and method for detecting infectious disease"
PROBLEM TO BE SOLVED: To provide an effective evaluation method and screening method of a substance having action lowering pathogenesis of pathogenic bacterium having gliding ability, to provide an effective medicine for prophylaxis and treatment of infectious diseases caused by the pathogenic bacterium, and to provide a method for producing the medicine and to provide a method for effectively evaluating pathogenesis of the pathogenic bacterium and a method for detecting infectious diseases caused by the pathogenic bacterium.
SOLUTION: The present invention provides an evaluation method and a screening method of a substance, having action for lowering pathogenesis of the pathogenic bacterium by using lowering of gliding activity of a pathogenic bacteria, having gliding ability as index and provides a medicine for prophylaxis and treatment of infectious diseases caused by the pathogenic bacterium, containing a substance having action lowering gliding activity of pathogenic bacteria having gliding ability as an active ingredient and provides a method for producing medication and provides an evaluation method of pathogenesis of the pathogenic bacteria, comprising evaluating the gliding activity of pathogenic bacteria having gliding ability, and a method for detecting infectious diseases caused by the pathogenic bacteria.
Issued - Jan 27, 2012
Genome Pharmaceuticals Institute Co., Ltd., The University of Tokyo
Patent Application Number:
JP 2011-116485
Patent Title:
"Novel cyclic peptide compound and method for producing the same, as well as anti-infective agent"
PROBLEM TO BE SOLVED: To provide a novel compound which has a high therapeutic effect, which is a novel compound having a chemical structure different from that of a conventional medicament, which is a novel compound also effective in multidrug-resistant bacteria, and which can be expected to have a low hurdle for practical application by selecting a target compound from a lot of candidate compounds through evaluation for not only an antibacterial activity but also for a therapeutic effect.
SOLUTION: The novel compound is a novel cyclic peptide compound produced by Lysobacter, or a pharmaceutically acceptable salt thereof.
Filed - May 25, 2011
Genome Pharmaceuticals Institute Co., Ltd., The University of Tokyo
Patent Application Number:
JP 2010-519750
Patent Title:
"Hypoglycemic agent, and food or beverage for prevention of diabetes or amelioration of condition of diabetes comprising same"
Disclosed is a hypoglycemic agent which rarely has the adverse side effects produced by conventional type-2 diabetes therapeutic agents, can be ingested or can be used for prophylactic purposes for a long period with few problems, and is suitable for use in foods and beverages. Specifically disclosed are: a hypoglycemic agent characterized by comprising galactose, a galactose derivative or an isolated galactose homopolymer as an active ingredient; a food or beverage for preventing diabetes or ameliorating the condition of diabetes, which comprises the hypoglycemic agent; and a food or beverage characterized by comprising galactose, a galactose derivative or an isolated galactose homopolymer as an active ingredient for the reduction in blood glucose level.
Filed - Jul 8, 2008
Genome Pharmaceuticals Institute Co., Ltd., The University of Tokyo
Patent Number:
JP 5219013
Patent Title:
"Method for evaluating and screening substance having activity for alleviating side effect of a medicine and side effect alleviating agent containing substance identified by these methods as effective component"
PROBLEM TO BE SOLVED: To provide a method for efficiently and easily evaluating and screening the substance for alleviating the side effect of a medicine on an organism having an acquired immunological mechanism, and a side effect alleviating agent for alleviating the side effect of the medicine on the organism having the acquired immunological mechanism by utilizing the substance evaluated and screened by that method.
SOLUTION: The evaluation method includes the process (a) of admistering the medicine and a substance to be examined to the organism having only a natural immunological mechanism, the process (b) of detecting the side effect of the medicine on the organism having the natural immunological mechanism and the process (c) of evaluating whether the substance to be examined alleviates the side effect and the screening method further includes the process (d) of selecting the substance evaluated to alleviate the side effect. The side effect alleviating agent contains edible oil as an effective component to alleviate the side effect of the medicine.
Issued - Mar 15, 2013
Genome Pharmaceuticals Institute Co., Ltd., The University of Tokyo and Nobelpharma Co., Ltd.
Patent Number:
JP 4468299
Patent Title:
"Method of screening bacterial growth inhibitort"
It is intended to provide a means of inhibiting the growth of a bacterium. Namely, a screening method based on a phenomenon occurring via a gene encoding at least one amino acid sequence selected from among those represented by SEQ ID NOS:3, 6 and 9 in the presence of a test sample, the dynamic state of a polypeptide encoded thereby or its fragment, or a temperature-sensitive mutant of the gene having a mutation.
Issued - Mar 5, 2010
Genome Pharmaceuticals Institute Co., Ltd., The University of Tokyo and Shionogi & Co. Ltd.
Patent Number:
JP 4716376
Patent Title:
"Method of temperature-dependently controlling the expression amount of target protein"
It is found out that the expression amount of a protein can be temperature-dependently controlled by culturing a cell containing a mutant gene encoding the target protein, which is constructed by substituting at least one of amino aid-encoding codons in a gene encoding the target protein by a stop codon, and a factor participating in read through contained in Staphylococcus aureus. Use of this method of controlling the expression amount of a protein makes it possible to analyze the function of the protein, construct a temperature-sensitive strain in the case of requiring the target protein in the proliferation of a microorganism, and identify a protein essentially required for the proliferation. Moreover, an antimicrobial agent can be screened by using the temperature-sensitive strain thus constructed or targeting the proliferation protein thus identified.
Issued - Apr 8, 2011
Genome Pharmaceuticals Institute Co., Ltd., The University of Tokyo and Shionogi & Co. Ltd.
Patent Number:
JP 5468750
Patent Title:
"Innate immunity overactivation inhibitor and method for screening the same"
PROBLEM TO BE SOLVED: To provide a method for screening innate immunity overactivation inhibitors, whereby overactivated state of innate immunity can be easily induced with high reproducibility, agents for preventing and improving the overactivated state of innate immunity can be screened and pharmacological examination of the agents can be achieved, the innate immunity overactivation inhibitor discovered thereby, and a model animal etc., displaying the overactivated state of innate immunity.
SOLUTION: The method for screening the innate immunity overactivation inhibitor screens a test substance using degree of amelioration of symptoms or death of insect larva as an index, provided that the symptoms or death are induced by administration of periodontal disease-causing bacteria and/or killed periodontal disease-causing bacteria and/or a peptidoglycan of periodontal disease-causing bacteria. The test substance discovered by the method is used as the innate immunity overactivation inhibitor.
Filed - Feb 7, 2014
Genome Pharmaceuticals Institute Co., Ltd., The University of Tokyo and Imagine Global Care Corporation,
Patent Application Number:
JP 2011-124011
Patent Title:
"Method for identifying target protein of antimicrobial agent based on analysis of drug-resistant and temperature-sensitive mutant strain"
PROBLEM TO BE SOLVED: To provide a method for identifying a target protein of "antimicrobial agent" such as an antibiotic, and a method of identifying a base substitution causing a drug resistance to be obtained.
SOLUTION: The method for identifying the target protein of the antimicrobial agent includes: isolating a temperature-sensitive mutant strain from among drug-resistant mutant strains against the agent; identifying the protein into which an amino acid mutation in the temperature-sensitive mutant is introduced; and identifying a protein before the amino acid mutation is introduced, as the target protein of the antimicrobial agent.
Filed - Jun 6, 2011
Genome Pharmaceuticals Institute Co., Ltd., The University of Tokyo
Patent Application Number:
JP 2013-092830
Patent Title:
"Toxicity testing method"
PROBLEM TO BE SOLVED: To provide a toxicity testing method capable of substituting an acute toxicity test to various medicines, food materials or the like by mammals having not only economic and troublesome problems but also many ethical problems with little financial and ethical problems and without reducing test significance.
SOLUTION: The toxicity testing method is a method for evaluating acute toxicity of cytotoxicity to mammals for an object to be tested showing cytotoxicity to mammals, a toxicity testing method to be performed by measuring a metabolic state of the object to be tested in a silkworm with the object to be tested administered thereto, a method for estimating a metabolic state in a mammal of the object to be tested, and is a drub metabolism estimation method which uses a silkworm as an experimental animal for substituted for a mammal.
Filed - Apr 25, 2013
Genome Pharmaceuticals Institute Co., Ltd.,
